<?xml version="1.0" ?>
<document id="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5">
  <chunk id="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c0" text="Citation: Targeted NGS Platforms for Genetic Screening and Gene Discovery in Primary Immunodeficiencies"/>
  <chunk id="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c1" text="Background: Primary Immunodeficiencies (PIDs) are a heterogeneous group of genetic immune disorders. While some PIDs can manifest with more than one phenotype, signs, and symptoms of various PIDs overlap considerably. Recently, novel defects in immune-related genes and additional variants in previously reported genes responsible for PIDs have been successfully identified by Next Generation Sequencing (NGS), allowing the recognition of a broad spectrum of disorders."/>
  <chunk id="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c2" text="Objective: To evaluate the strength and weakness of targeted NGS sequencing using custom-made Ion Torrent and Haloplex (Agilent) panels for diagnostics and research purposes.">
    <entity charOffset="94-97" id="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c2.e0" ontology_id="CHEBI_24870" text="Ion" type="chemical"/>
  </chunk>
  <chunk id="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c3" text="Cifaldi et al."/>
  <chunk id="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c4" text="Methods: Five different panels including known and candidate genes were used to screen 105 patients with distinct PID features divided in three main PID categories: T cell defects, Humoral defects and Other PIDs. The Ion Torrent sequencing platform was used in 73 patients. Among these, 18 selected patients without a molecular diagnosis and 32 additional patients were analyzed by Haloplex enrichment technology.">
    <entity charOffset="114-117" id="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c4.e0" ontology_id="CHEBI_8066" text="PID" type="chemical"/>
    <entity charOffset="114-117" id="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c4.e1" ontology_id="DOID_1003" text="PID" type="disease"/>
    <entity charOffset="149-152" id="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c4.e2" ontology_id="CHEBI_8066" text="PID" type="chemical"/>
    <entity charOffset="149-152" id="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c4.e3" ontology_id="DOID_1003" text="PID" type="disease"/>
    <entity charOffset="217-220" id="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c4.e4" ontology_id="CHEBI_24870" text="Ion" type="chemical"/>
    <pair e1="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c4.e1" e2="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c4.e4" id="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c4.p0" relation="true"/>
    <pair e1="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c4.e3" e2="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c4.e4" id="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c4.p1" relation="true"/>
  </chunk>
  <chunk id="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c5" text="Results: The complementary use of the two custom-made targeted sequencing approaches allowed the identification of causative variants in 28.6% (n = 30) of patients. Twenty-two out of 73 (34.6%) patients were diagnosed by Ion Torrent. In this group 20 were included in the SCID/CID category. Eight out of 50 (16%) patients were diagnosed by Haloplex workflow. Ion Torrent method was highly successful for those cases with welldefined phenotypes for immunological and clinical presentation. The Haloplex approach was able to diagnose 4 SCID/CID patients and 4 additional patients with complex and extended phenotypes, embracing all three PID categories in which this approach was more efficient. Both technologies showed good gene coverage.">
    <entity charOffset="221-224" id="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c5.e0" ontology_id="CHEBI_24870" text="Ion" type="chemical"/>
    <entity charOffset="359-362" id="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c5.e1" ontology_id="CHEBI_24870" text="Ion" type="chemical"/>
    <entity charOffset="636-639" id="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c5.e2" ontology_id="CHEBI_8066" text="PID" type="chemical"/>
    <entity charOffset="636-639" id="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c5.e3" ontology_id="DOID_1003" text="PID" type="disease"/>
    <pair e1="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c5.e0" e2="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c5.e3" id="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c5.p0" relation="true"/>
    <pair e1="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c5.e1" e2="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c5.e3" id="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c5.p1" relation="true"/>
  </chunk>
  <chunk id="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c6" text="Conclusions: NGS technology represents a powerful approach in the complex field of rare disorders but its different application should be weighted. A relatively small NGS target panel can be successfully applied for a robust diagnostic suspicion, while when the spectrum of clinical phenotypes overlaps more than one PID an in-depth NGS analysis is required, including also whole exome/genome sequencing to identify the causative gene.">
    <entity charOffset="317-320" id="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c6.e0" ontology_id="CHEBI_8066" text="PID" type="chemical"/>
    <entity charOffset="317-320" id="6b74be7b5e6870fb9f10027347b2ad067aa8b4d5.c6.e1" ontology_id="DOID_1003" text="PID" type="disease"/>
  </chunk>
</document>
